Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Zaanen, H.C.T. van"'
Autor:
Kersting, S., Dubois, J., Nasserinejad, K., Dobber, J.A., Mellink, C., Kevie-Kersemaekers, A.M.F. van der, Evers, L.M., Boer, F. de, Koene, H.R., Schreurs, J., Klift, M. van der, Velders, G.A., Spek, E. van der, Straaten, H.M. van der, Hoogendoorn, M., Gelder, M. van, Posthuma, E.F.M., Visser, H.P.J., Houtenbos, I., Idink, C.A.M., Issa, D.E., Dompeling, E.C., Zaanen, H.C.T. van, Veelken, H., Levenga, H., Tick, L.W., Terpstra, W.E., Tonino, S.H., Boyer, M., Mobasher, M., Levin, M.D., Kater, A.P., HOVON CLL Study Grp
Publikováno v:
The Lancet Haematology, 9(3), E190-E199. ELSEVIER SCI LTD
Background Fixed-duration 12 cycles of venetoclax plus obinutuzumab is established as first-line treatment for patients with chronic lymphocytic leukaemia. We aimed to determine the activity and safety of 12 cycles of venetoclax consolidation after f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::3040ad5dcc587d05eb70b232e6f18437
https://hdl.handle.net/1887/3566433
https://hdl.handle.net/1887/3566433
